Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • A ‘milestone’ moment: why economists think the global cycle of rate rises is over
    • Lawmakers warn that US is heading for shutdown as budget talks stall
    • OSCE in crisis as Russian veto threatens security body
    • Olaf Scholz accuses Poland of ‘waving through’ refugees as visa scandal deepens
    • Russia dodges G7 price cap sanctions on most of its oil exports
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Private equity firms pivot away from traditional buyouts
      • Senior Nomura banker barred from leaving mainland China
      • Lego ditches oil-free brick in sustainability setback
      • German fintech Solaris struggles to raise funds to execute major contract
      • Sale of THG boss’s business park falls through
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Hedge funds rush to unwind bets against gilts
      • Jeremy Hunt plans Isa overhaul to boost share ownership
      • Russia dodges G7 price cap sanctions on most of its oil exports
      • Singapore banks tighten scrutiny of clients after money-laundering scandal
      • German fintech Solaris struggles to raise funds to execute major contract
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A multi-speed Europe holds the key to EU enlargement
      • America’s mini economic miracle may be fleeting
      • Populism could derail the green transition
      • The wage growth puzzle for central banks
      • How to save your state pension
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • What Burberry taught me about the marketed mind
      • The activist sued by Elon Musk: ‘We have to show we will not be cowed’
      • Paternity leave in finance: ‘The more men do it, the less of a big deal it becomes’
      • Success is more complicated than one exceptional individual
      • FT Business Books — what to read this month
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Raffles London and the new era of super-luxe hospitality
      • Anna Wintour: ‘I just have to make sure things are being done right’
      • The best museum gift shops in the world
      • 17 chefs share the side dishes they can’t do without
      • Who’d invite the boss to dinner?
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Dementia

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Tuesday, 18 July, 2023
      LexDrugs research
      Alzheimer’s drugs: new medicines bring new hope to dementia battle Premium content

      Promising trial results will not end scientific debate over the disease, but they further validate pharmaceutical research

      Brain scan from a patient suffering from Alzheimer’s disease
    • Monday, 17 July, 2023
      Eli Lilly drug shown to slow Alzheimer’s progression

      Dementia experts hail ‘watershed moment’ after trial results for donanemab antibody treatment

      Alzheimer’s patient brain scans, provided by Eli Lilly
    • Thursday, 6 July, 2023
      US regulators approve first drug to slow progression of Alzheimer’s

      Move by Food and Drug Administration paves way for millions of Americans to access medicine

      Vials and packaging for the medication Leqembi
    • Monday, 3 July, 2023
      The Big Read
      How a Swedish start-up reignited the search for an Alzheimer’s drug

      A decade ago a large part of Big Pharma gave up on one of humanity’s cruellest diseases. But then a new treatment showed promise

    • Friday, 9 June, 2023
      Camilla Cavendish
      An ageing society can’t turn its back on social care any longer

      Governments have promised to tackle the crisis for 25 years, but it’s never an election winner

      Illustration of a frail elderly man with glasses sitting at a table in front of a paisley wallpapered wall
    • Sunday, 14 May, 2023
      Japan pushes for strong pledges on tackling dementia from G7 allies

      Alzheimer’s advocates call for ambitious declaration to match the scope of commitments made 10 years ago

      Alzheimer’s brain scan
    • Monday, 8 May, 2023
      Two Alzheimer’s drugs offer hope to patients after decades of waiting

      In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

      Computer scan of a brain
    • Wednesday, 3 May, 2023
      Eli Lilly & Co
      Eli Lilly to seek US approval after Alzheimer’s drug trial success

      Clinical study results could boost patient access to new class of treatment

      Eli Lilly logo is shown on one of the company’s offices
    • Wednesday, 19 April, 2023
      ReviewFT Books Essay
      Alternative realities: caring for people with dementia

      With an ageing global population, cases of the disease continue to drastically rise. Two timely and insightful books offer help on how to support the millions of new patients

      A woman hugs her mother who is seated in front of a mural
    • Monday, 20 February, 2023
      OutlookPatti Waldmeir
      How banks may catch signs of dementia before the doctors do

      Money problems experienced by elderly customers can be red flags for families and institutions alike

      Customers use an automated teller machine at a Citibank branch in Chicago, Illinois
    • Wednesday, 11 January, 2023
      Anjana Ahuja
      New Alzheimer’s drug straddles uneasy gulf between help and harm

      For all its landmark status, lecanemab may end up representing a triumph of hope over evidence

      Illustration of a man falling into darkness (to represent Alzheimer’s) and the rope coming down from the light is a spiky vine to suggest the ‘help’ can still cause harm
    • Thursday, 29 December, 2022
      Biogen Inc
      Congress faults US regulator’s approval of Biogen Alzheimer’s drug

      Committees cite inappropriate collaboration between FDA and drugmaker

      A box of the Aduhelm drug
    • Friday, 2 December, 2022
      Pharmaceuticals sector
      Swedish scientist behind Alzheimer’s drug has big ambitions

      Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s

      Lars Lannfelt, inventor of the ground-breaking drug lecanemab
    • Friday, 2 December, 2022
      The editorial board
      A glimmer of hope in treating Alzheimer’s disease

      Dementia drug development, diagnostics and delivery still require much more investment

      A series of brightly coloured scans of brain activity
    • Wednesday, 30 November, 2022
      Eisai says Alzheimer’s drug did not cause deaths of trial patients

      Japanese company refuses to rule out possibility treatment contributed to brain bleeds

    • Tuesday, 29 November, 2022
      Eisai Co Ltd
      Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

      Shares fall 11% following two patient deaths in trials of lecanemab

      Haruo Naito, the 74-year-old chief executive of Japan’s Eisai
    • Monday, 28 November, 2022
      LexDrugs research
      Dementia/Biogen: causal controversy means investors must take a stance Premium content

      The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

    • Monday, 14 November, 2022
      Roche Holding AG
      Roche late-stage Alzheimer’s trials end in failure

      Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

      A brain scan showing Alzheimer’s disease
    • Sunday, 13 November, 2022
      Insurance
      AI is giving insurers godlike powers, says Sompo chief

      Access to large data sets means predictions are far more accurate in reducing risk

      Elderly people exercising in Tokyo
    • Monday, 24 October, 2022
      Evidence builds of viruses’ role in Alzheimer’s disease

      Researchers focus on pathogens including Covid, herpes and Epstein-Barr virus

      senior woman sitting alone in her living room looking out a window
    • Wednesday, 28 September, 2022
      Pharmaceuticals sector
      Biogen and Eisai shares surge after Alzheimer’s drug trial success

      Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

      A scan of a brain affected by Alzheimer’s disease
    • Friday, 23 September, 2022
      Health sector
      Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

      Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts

      A section of a human brain with Alzheimer’s disease on display at the Museum of Neuroanatomy at the University at Buffalo, New York
    • Monday, 22 August, 2022
      Medical science
      Electrical brain stimulation improves memory in elderly, research finds

      Study could be used to help boost cognitive performance of people developing Alzheimer’s disease

      A researcher at Boston University administers the brain stimulation to a study participant
    • Wednesday, 17 August, 2022
      Coronavirus
      Covid can cause brain disorders two years after infection, study shows

      Long-term effects are generally less in children, although infection doubles risk of epilepsy

      Commuters arrive at King’s Cross railway station in London
    • Wednesday, 18 May, 2022
      Coronavirus
      How can Covid-19 affect the human brain?

      Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting

      FT montage of MRI scan brain images
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In